Roche Report High Response Rate in Lung Cancer Drug Trial


presents updated data on investigational immunotherapy MPDL3280A (anti-PDL1) in cancer at ECC 2013
Rapid and durable responses observed in difficult-to-treat patients
Data suggest tumor PD-L1 biomarker status predictive of treatment efficacy

Basel, 29 September  2013 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company has presented important new data on MPDL3280A (RG7446, also known as anti-PDL1) at the 2013 European Cancer Congress (ECC), September 27 to October 1, 2013, in Amsterdam, The Netherlands. These data were highlighted as part of ECC 2013’s official press program.

The data from an updated analysis of a Phase 1 study assessing MPDL3280A monotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) showed that MPDL3280A was generally well tolerated and yielded often rapid, durable responses. rates were particularly in patients who had greater expression of PD-L1 in their tumors as measured by a Roche Tissue Diagnostics immunohistochemistry (IHC) assay.

“These results in patients with limited treatment options for their lung cancer are encouraging, and PD-L1 expression could help determine which patients derive the most benefit,” said Hal Barron, MD, Chief Medical Officer and Head of Global Product Development at Roche. “Based on these data, we are moving quickly into late-stage clinical studies that will also include a Roche companion diagnostic to potentially identify those who are more likely to respond to treatment.”

MPDL3280A is an investigational medicine designed to make cancer cells more vulnerable to the body’s immune system, referred to more broadly as cancer immunotherapy, by interfering with a protein called PD-L1 (Programmed Death-Ligand 1). PD-L1 is expressed in tumors and is believed to function as a key part of the cancer-immunity cycle by acting as a ‘stop sign’, preventing the immune system from destroying cancer…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS